Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy.

Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA.

J Interv Cardiol. 2010 Oct;23(5):429-36. doi: 10.1111/j.1540-8183.2010.00561.x. Epub 2010 Aug 31.

PMID:
20819117
2.

Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention.

Huang RI, Patel P, Walinsky P, Fischman DL, Ogilby JD, Awar M, Frankil C, Savage MP.

Catheter Cardiovasc Interv. 2006 Nov;68(5):671-6.

PMID:
17034064
3.

Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction.

Kobatake R, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, Saito H, Ujihira T.

Heart Vessels. 2011 Jul;26(4):379-84. doi: 10.1007/s00380-010-0065-5. Epub 2010 Nov 26.

PMID:
21110199
4.

Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol.

Niccoli G, D'amario D, Spaziani C, Cosentino N, Marino M, Rigattieri S, Schiavo PL, De Vita MR, Tarantino F, Bartorelli A, Fabbiocchi F, Prati F, Imola F, Valgimigli M, Ferrari R, Crea F.

J Cardiovasc Med (Hagerstown). 2009 Jul;10(7):585-92. doi: 10.2459/JCM.0b013e32832b3571.

PMID:
19384242
5.

Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.

Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, Weinstein JM, Wolak A, Ilia R, Zahger D.

Am Heart J. 2006 Nov;152(5):887.e9-14.

PMID:
17070151
6.

No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention.

Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CD, Popma JJ, Piana R.

Am Heart J. 2003 Jan;145(1):42-6.

PMID:
12514653
7.
8.
9.

5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction.

Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schömig A, Kastrati A.

J Am Coll Cardiol. 2010 May 25;55(21):2383-9. doi: 10.1016/j.jacc.2009.12.054.

10.

Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty.

Tanzilli G, Greco C, Pasceri V, Pelliccia F, Arrivi A, Placanica A, Mangieri E.

Catheter Cardiovasc Interv. 2010 Nov 15;76(6):787-93. doi: 10.1002/ccd.22724. Epub 2010 Aug 24.

PMID:
20737584
11.

Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow.

Hendler A, Aronovich A, Kaluski E, Zyssman I, Gurevich Y, Blatt A, Reicher M, Leitman M, Czuriga I, Vered Z, Krakover R.

J Invasive Cardiol. 2006 Jan;18(1):32-6.

PMID:
16391383
12.

Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.

Werner GS, Lang K, Kuehnert H, Figulla HR.

Catheter Cardiovasc Interv. 2002 Dec;57(4):444-51.

PMID:
12455077
13.

Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.

Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ, Jessurun GA, Anthonio RL, van den Heuvel AF, Tan ES, Zijlstra F.

Circ Cardiovasc Interv. 2009 Aug;2(4):323-9. doi: 10.1161/CIRCINTERVENTIONS.109.858977.109.858977. Epub 2009 Jul 22.

14.

Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.

Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, Avanzas P, Bosa-Ojeda F, Kaski JC.

Am J Cardiol. 2010 Dec 1;106(11):1540-4. doi: 10.1016/j.amjcard.2010.07.030. Epub 2010 Oct 14.

PMID:
21094352
15.

Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.

Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, Nishikawa N, Higashino Y, Fujii K, Minamino T.

J Am Coll Cardiol. 1997 Nov 1;30(5):1193-9.

16.

No-reflow: Still searching for that magic bullet.

Gilchrist IC.

Catheter Cardiovasc Interv. 2010 Nov 15;76(6):794. doi: 10.1002/ccd.22849. No abstract available.

PMID:
21104769
17.

Direct transfer of ST-elevation myocardial infarction patients for primary percutaneous coronary intervention from short and long transfer distances decreases temporal delays and improves short-term prognosis: the PROGALIAM Registry.

Estévez-Loureiro R, Calviño-Santos R, Vázquez-Rodríguez JM, Marzoa-Rivas R, Barge-Caballero E, Salgado-Fernández J, Aldama-López G, Barreiro-Díaz M, Varela-Portas J, Freire-Tellado M, Vázquez-González N, Castro-Beiras A.

EuroIntervention. 2010 Aug;6(3):343-9. doi: 10.4244/EIJV6I3A57.

PMID:
20884412
18.

Features and outcome of no-reflow after percutaneous coronary intervention.

Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, Safian RD.

Am J Cardiol. 1995 Apr 15;75(12):778-82.

PMID:
7717278
20.

The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction.

Tesic MB, Stankovic G, Vukcevic V, Ostojic MC.

Herz. 2010 Mar;35(2):114-8. doi: 10.1007/s00059-010-3243-4. Epub 2010 Apr 8.

PMID:
20376646
Items per page

Supplemental Content

Write to the Help Desk